America’s Essential Hospitals asked U.S. Health and Human Services Secretary Xavier Becerra late last week “to swiftly remedy five years of unlawful drug reimbursement cuts to 340B
hospitals under Medicare Part B.”
“These cuts, and a delay in recompensing hospitals for
…
Identical bills have been introduced in the Iowa House and Senate to bar pharmacy benefit managers and insurers from using alleged discriminatory practices against 340B covered entities and their contract pharmacies, including reimbursing them at a lower rate or imposing
…
Johnson & Johnson, the world’s biggest drug company, yesterday announced a major expansion of the drug industry’s campaign to set limits on 340B drug sales.
On March 7, it is poised to become the first drug maker to place a
…
Connecticut’s Democratic governor wants his state’s 340B hospitals to start filing annual reports disclosing their 340B drug revenues and summarizing how they use the money to benefit their communities. Health centers and other 340B grantee covered entities would be exempt
…
SPONSORED CONTENT
This past November, the 340B program celebrated its 30th anniversary—a huge milestone and a reason to rejoice and reflect. We are dismayed, however, that certain drug manufacturers are trying to revise the 340B program’s past and reimagine its future. More than 20 drug manufacturers have unilaterally and unlawfully placed restrictions on contract pharmacy arrangements which have diminished the value of the 340B programs for communities in need. [1] However, it is vital to note that, in the last thirty years, the need for outpatient drugs to treat patients has grown exponentially, as has the price of drugs, making the 340B program more crucial than ever for safety net providers and their patients.
Most of us know that Congress passed the 340B statute in 1992 to enable covered entities “to stretch scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive services.” But did you know that, when Congress was drafting the
…
U.S. Sen. Tammy Baldwin (D-Wis.), who has a long track record of support for 340B covered entities, is the new leader of a Senate Appropriations subcommittee with influence over 340B policy.
Baldwin announced yesterday she will serve as chair
…
Q: Where did you grow up?
I grew up in Pacific Beach, San Diego, a lovely little beach town.
Q: Where did you go to college?
I attended
…
Health care providers in the coming months may get previously unavailable access to 340B pricing on contrast agents, radiopharmaceuticals, and so-called “OTC monograph” drugs thanks to language tucked into the massive fiscal year 2023 federal spending bill signed into law
…
Seema Verma, ex-President Trump’s Centers for Medicare & Medicaid Services administrator, said in a Wall Street Journal op-ed yesterday that large health systems work to expand their use of the 340B program “and thus their profit and monopoly power.”
“Across
…
The U.S. Centers for Medicare & Medicaid Services is seeking comments by March 11 on “the most reliable way to identify” 340B-purchased drugs dispensed to Medicare Part D beneficiaries so they can be excluded from new Part D inflation rebate
…*Sign up for news summaries and alerts from 340B Report
